Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications.

导出 OA

翻译打印收藏纠错

作者： Shalini S,Yadav ^[1] ; Jinyi,Li ^[1] ; Jennifer A,Stockert ^[1] ; Bryan,Herzog ^[1] ; James,O'Connor ^[1] ; Luis,Garzon-Manco ^[1] ; Ramon,Parsons ^[2] ; Ashutosh K,Tewari ^[1] ; Kamlesh K,Yadav ^[3]

作者单位： Department of Urology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029-6574. ^[1] Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029-6574. ^[2] Department of Urology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029-6574. Electronic address: kamlesh.yadav@mountsinai.org. ^[3]

DOI 10.1016/j.tranon.2017.01.011

PMID 28342996

发布时间 2020-10-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览16

Translational oncology

2017年10卷3期

357-366页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications.

Translational oncology

相似文献

Translational oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications.

Translational oncology

相似文献

Translational oncology

相关期刊

检索历史清除